LBLuca Battistelli

Luca Battistelli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Luca Battistelli has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Validation of a quantitative PCR-high-resolution melting protocol for simultaneous screening ofCOL1A1andCOL1A2point mutations and large rearrangements: Application for diagnosis of osteogenesis imperfecta

    by Filomena Valentina Gentile, Monia Zuntini, Alessandro Parra, Luca Battistelli, Martina Pandolfi, Gerard Pals, Luca Sangiorgi

    Osteogenesis imperfecta (OI) is a connective tissue disorder mostly characterized by autosomal dominant inheritance. Over 1,100 causal mutations have been identified scattered along all exons of genes encoding type I collagen precursors, COL1A1 and COL1A2. Because of the absence of mutational hotspots, Sanger sequencing is considered the gold standard for molecular analysis even if the workload is very laborious and expensive. To overcome this issue, different prescreening methods have been proposed, including DHPLC and biochemical studies on cultured dermal fibroblasts; however, both approaches present different drawbacks. Moreover, in case of patients who screen negative for point mutations, an additional screening step for complex rearrangements is required; the added causative variants expected from this approach are about 1–2%. The aim of this study was to optimize and validate a new protocol that combines quantitative PCR (qPCR) and high‐resolution melting (HRM) curve analysis to reduce time and costs for molecular diagnosis. Results of qPCR–HRM screening on 57 OI patients, validated by DHPLC–direct sequencing and multiplex ligation‐dependent probe amplification (MLPA), indicate that all alterations identified with the mentioned methodologies are successfully detected by qPCR–HRM. Moreover, HRM was able to discriminate complex genotypes and homozygous variants. Finally, qPCR–HRM outperformed direct sequencing and DHPLC–MLPA in terms of rapidity and costs. Hum Mutat 33:1697–1707, 2012.


  • Molecular basis of osteoclastogenesis induced by osteoblasts exposed to wear particles

    by Donatella Granchi, Ilaria Amato, Luca Battistelli, Gabriela Ciapetti, Stefania Pagani, Sofia Avnet, Nicola Baldini, Armando Giunti


    • 28 July 2004
      • Vol. 24, 1705-11

    Isolation and characterization of a new cell line from a renal carcinoma bone metastasis.

    by Sofia Avnet, Elisabetta Cenni, Donatella Granchi, Francesca Perut, Ilaria Amato, Luca Battistelli, Maria Luisa Brandi, Armando Giunti, Nicola Baldini

    The use of cell lines isolated from metastases should enable the assessment of peculiar aspects of bone resorbing cytokine expression, as well as angiogenetic activity of renal carcinoma bone metastases. A cell line (CRBM-1990) was isolated from a renal cell carcinoma bone metastasis and compared with the ACHN and Caki-1 established lines. The expression of osteolytic cytokine and angiogenetic growth factors mRNAs, as well as the effect on migration and proliferation of a bovine bone cell line (BBE) were determined. There were no significant differences between the three lines in IL-6, TGF-beta, VEGF-A, VEGF-B, VEGF-C and FGF-2 mRNAs expression. VEGF-D, PIGF, or RANK-L-specific mRNA were not expressed. CRBM-1990-, Caki-1- and ACHN-conditioned media significantly stimulated the migration and proliferation of BBE. CRBM-1990 expressed IL-6-specific mRNA, but not RANK-L, expressed angiogenetic growth factors and induced migration and proliferation of bone endothelial cells at a non-significantly different level when compared with Caki-1 and ACHN.


  • Open Access

    In vitro blockade of receptor activator of nuclear factor‐κB ligand prevents osteoclastogenesis induced by neuroblastoma cells

    by Donatella Granchi, Ilaria Amato, Luca Battistelli, Sofia Avnet, Sergio Capaccioli, Laura Papucci, Martino Donnini, Andrea Pellacani, Maria Luisa Brandi, Armando Giunti, et al.

    Proliferation and differentiation of osteoclasts are regulated by a cytokine system that includes RANKL, which binds 2 receptors: RANK, which activates osteoclast differentiation, and osteoprotegerin (OPG), a decoy receptor that limits RANKL action. We investigated the role of the OPG/RANKL/RANK network in the pathogenesis of skeletal metastasis in neuroblastoma. Four different neuroblastoma cell lines (NB100, CHP212, SH‐SY5Y, SJ‐NK‐P) showed a large amount of OPG and RANKL transcripts. Soluble RANKL was detectable in all cell lines, but poor release of OPG was observed. SH‐SY5Y showed the lowest OPG‐to‐RANKL ratio and promoted osteoclastic differentiation of FLG29.1 and peripheral mononuclear cells, inducing expression of the osteoclast markers RANK, c‐src, c‐fos, cathepsin‐K and TRAP. SJ‐N‐KP, which released both OPG and RANKL, did not show the same capability. OPG, neutralizing anti‐RANKL antibody and antisense oligonucleotides were evaluated for their ability to inhibit RANKL activity. The neutralizing antibody hampered osteoclastic differentiation by blocking both the juxtacrine and the paracrine activity of RANKL. Our findings confirm that neuroblastoma cells induce osteoclastogenesis via RANKL and suggest that the RANKL expression associated with lack of the decoy receptor OPG could be a peculiarity of some tumors that makes them able to induce metastatic osteolysis. Moreover, our results suggest that RANKL could be a relevant target in the adjuvant therapy of bone metastatic neuroblastoma as proper neutralization revokes completely osteoclastic differentiation.